Combination Therapy, PDE5 and Acute Urinary Retention

Two drugs, two entirely different jobs

The obstruction in BPH has two components — one you can relax in days, one you can only shrink over months. The dynamic component is smooth-muscle tone in the prostate and bladder neck, driven by alpha-1 adrenoceptors. An alpha-blocker — tamsulosin, alfuzosin, doxazosin — relaxes that tone and improves the stream within days. This is fast symptom relief, but it changes nothing about the size of the gland. The static component is the sheer bulk of prostate tissue, and its growth is driven by dihydrotestosterone (DHT), the potent androgen made from testosterone by the enzyme 5-alpha-reductase. A 5-alpha-reductase inhibitor (5-ARI) — finasteride or dutasteride — starves the gland of DHT, and over three to six months the prostate actually shrinks by roughly a fifth. Crucially, the 5-ARI is the only class shown to reduce the long-term risk of disease progression and acute urinary retention. Put the two together — the fast relaxer plus the slow shrinker — and you treat both components at once. The full mechanism of each class lives in the Alpha-blocker and 5-alpha-reductase inhibitor chapters; here we combine them.

Combination therapy is not for everyone — it is aimed at the man with a larger gland and a higher risk of progression, exactly the population studied in the landmark MTOPS and CombAT trials, where combining an alpha-blocker with a 5-ARI beat either drug alone at preventing clinical progression and retention. For a man with a small prostate and only mild symptoms, an alpha-blocker alone is usually enough, and adding a 5-ARI buys little. There is also an elegant sequencing trick: because the 5-ARI physically shrinks the gland over time, in some men the alpha-blocker can be withdrawn after six to twelve months once the gland has been reduced, leaving the 5-ARI to hold the ground alone. Start with both for fast relief plus long-term protection, then consider stepping down the relaxer once the shrinker has done its work.

The newer option: daily tadalafil, one drug for two problems

A drug born for erections turned out to relax the lower urinary tract too. Daily low-dose tadalafil, a phosphodiesterase-5 (PDE5) inhibitor, is licensed specifically for the lower urinary tract symptoms (LUTS) of BPH. Its mechanism is the same nitric-oxide pathway that gives it its more famous use: nitric oxide (NO) raises cyclic GMP (cGMP) in smooth muscle, and by blocking the PDE5 enzyme that breaks cGMP down, tadalafil keeps cGMP high — relaxing the smooth muscle of the prostate, bladder neck, and detrusor, and improving the pelvic blood supply. The clinical sweet spot is the man who has both BPH and erectile dysfunction, because a single daily tablet treats both problems at once — the mechanism is developed in full in the Erectile dysfunction / PDE5 chapter. But the same vasodilating action carries a warning: do not casually combine a PDE5 inhibitor with an alpha-blocker, because both drop blood pressure and the additive effect can cause symptomatic hypotension and fainting. And the absolute rule that never bends — a PDE5 inhibitor must never be given with nitrates, because the combined, unopposed rise in cGMP can cause catastrophic, life-threatening hypotension.

When storage symptoms won't quit: adding bladder-calming drugs

Some men, even after the outlet is opened up, are still tormented by storage symptoms — frequency, urgency, and nocturia — because the bladder muscle itself has become over-active. Here you add a drug that calms the detrusor: an antimuscarinic (solifenacin, tolterodine, oxybutynin), which blocks the muscarinic acetylcholine receptors that drive bladder contraction, or the beta-3 adrenoceptor agonist mirabegron, which relaxes the storage-phase bladder by a different route. These are the same drugs covered in the Overactive bladder chapters, borrowed here to layer storage relief on top of outlet treatment. But there is a genuine hazard: giving an antimuscarinic to a man with significant outflow obstruction can tip him into retention, precisely because you are weakening the bladder's ability to squeeze against a still-narrowed outlet. So the sequence matters — relieve the obstruction first, then add a bladder-calming drug carefully, and be especially wary in the man with a large post-void residual volume.

The emergency: acute urinary retention

A man who suddenly cannot pass urine, with a painfully distended bladder, is a genuine emergency. Acute urinary retention (AUR) is the sudden, painful inability to void, and the first move is not a drug at all — it is immediate catheterisation to drain the bladder and relieve the agony. Once the block is relieved, drugs and prevention take over. Start an alpha-blocker while the catheter is in, because it relaxes the outlet and measurably improves the chance of passing urine at the trial without catheter (TWOC) — the moment the catheter is removed to see if he can void on his own. If the gland is large, a 5-ARI is added to shrink it and lower the risk of retention returning. And every episode of retention has a trigger that must be hunted down and treated: constipation, a urinary tract infection, and — the pharmacology point that catches out students — culprit drugs. Anticholinergics (including many antihistamines, tricyclics and antimuscarinics), sympathomimetics (decongestants that tighten the bladder neck), and opioids can all precipitate retention. Stopping the offending drug may be the whole treatment. These drug triggers connect to the Toxicology chapter on anticholinergic and opioid effects.

There is one more trap after decompression that turns up in exams and on the ward: post-obstructive diuresis. When a chronically obstructed, over-full bladder is finally drained, the kidneys can pour out large volumes of urine for a day or two — a mix of appropriate offloading of retained fluid and a temporary loss of the kidney's ability to concentrate. In a big diuresis the patient can become volume-depleted and lose sodium and potassium, so after relieving a large retention you monitor urine output, fluid balance and electrolytes, and replace what is lost — the same fluid-and-electrolyte reasoning taught in the Cardiovascular and fluid-management chapters. Finally, when medical therapy genuinely fails — recurrent retention, or symptoms that persist despite optimal drugs — the man is referred for surgery, classically a transurethral resection of the prostate (TURP), which physically removes obstructing tissue. Drugs manage and prevent; surgery is the definitive relief when they are no longer enough.